Mallinckrodt's Opioid Resolution Through Generic Unit Bankruptcy May Be 'Test Case'
Executive Summary
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
You may also be interested in...
Walgreens And CVS Agree To Opioid Settlements, But States Waiting To See Details
As states weigh their options, the history of past settlements will be a factor. One state signed onto the settlement with the distributors but opted out of the deal with J&J, netting it millions more, and with faster payment, than it would have received under the national settlement.
J&J, Distributors May Be Free Of Opioid Litigation If Enough States Sign On To $26bn Settlement
NY AG has ‘no comment’ on whether criminal charges will be pursued against company executives; NC AG predicts ‘north of 40 states’ expected to accept settlement and would then need to convince municipalities to come on board. States with ongoing litigation against manufacturers may opt for jury trial instead.
Legislators Seek US FDA Input On Teva Proposed Opioid Settlement
Reps. McKinley and Kaptur ask commissioner Hahn about potential for shortages if Teva’s proposal to provide free opioid addiction treatment goes into effect. States are pushing for more money and stricter injunctive terms in settlement talks with manufacturers and distributers.